Tnf News

A Swedish study has concluded that rheumatoid arthritis patients did not experience an increased cancer risk in the first 6 years of treatment with TNF blockers .

During the past decade, a new class of drugs, called TNF inhibitors, has improved the lives of tens of thousands of people who suffer from painful autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.

Treatment with tumor necrosis factor blockers doesn't increase rheumatoid arthritis patients' risk of cancer, new research has found.

A recent study by Swedish researchers found that rheumatoid arthritis patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor therapy.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, ...

Cephalon, Inc. and BioAssets Development Corporation , a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor -alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established ...

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials Article Date: 23 Oct 2009 Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor -alpha inhibitors will continue to dominate first- and second-line biologic ...

For many people with rheumatoid arthritis , the traditional, and much cheaper, disease-modifying antirheumatic drugs appear to work just as well as newer TNF blockers that target the underlying disease process, a large study shows.

Children who once faced lifelong disabilities from arthritis seem to be getting relief from powerful but costly new medicines, according to studies presented in Philadelphia this week.

Oct 19, 2009 - Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel in a mouse model of arthritis.

People who take immune-disease drugs called TNF blockers for rheumatoid arthritis should check their bodies regularly for abnormal growths that can signal skin cancer .

National report - Experts disagree on the possible impact a new pediatric cancer warning for tumor necrosis factor inhibitors may have on this drug category's growth.

National report - Although hardly unexpected, the Food and Drug Administration's decision to add a warning about a possible link between tumor necrosis factor antagonists and cancer in children goes too far, say most dermatologists contacted by Dermatology Times .

Gastroenterologists in France generally follow recommendations for the use of anti-tumor necrosis factor and concomitant immunosuppressive therapy in inflammatory bowel disease, finds a study in Alimentary Pharmacology and Therapeutics .

TNF stands for Tumor Necrosis Factor. It is a secretion of certain immune system cells and a type of signaling molecule that carries messages between other immune system cells.

Ablynx [Euronext Brussels: ABLX], today announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth.

Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue Author affiliations: Oregon Health and Sciences University, Portland, Oregon, USA ; US Public Health Service, Washington, DC, USA ; and Centers for Disease Control and Prevention, Atlanta, Georgia, USA Suggested citation for this article Abstract Patients receiving antitumor ...

Original Contributions Production After Nuclear Factor- Cora H. Nijboer, PhD ; Cobi J. Heijnen, PhD ; Floris Groenendaal, MD, PhD ; Frank van Bel, MD, PhD Annemieke Kavelaars, PhD From the Laboratory of Psychoneuroimmunology and the Department of Neonatology , University Medical Center Utrecht, Utrecht, The Netherlands.

Protalix Biotherapeutics, Inc. , reported preclinical data on pr-antiTNF, a biosimilar version of etanercept .